Fractional RF lifting and tranexamic acid in the treatment of hypermelanosis
DOI: 10.32364/2587-6821-2025-9-6-7
N.Yu. Bychkova1,2, V.E. Lemytskaya3
1Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russian Federation
2RUDN University, Moscow, Russian Federation
3BTL Russia, Moscow, Russian Federation
This review addresses the topic of hypermelanosis, which is characterized by disturbances in melanin metabolism and the development of cosmetic defects that adversely impact patients' quality of life. The article highlights the challenges associated with the treatment of melanogenesis disorders, which require thorough analysis and precise diagnostic assessment before the therapy initiation. Particular attention is given to the potential risks associated with technologies aimed at melanin destruction, such as laser and light-based methods, which may result in iatrogenic complications and aggravation of pigmentation.
Pathogenetic therapy encompasses inhibition of melanin synthesis and its degradation, acceleration of epidermal turnover, and photoprotection. Topical agents such as hydroquinone, thiamidol, and retinoids are employed as first-line therapy, whereas chemical peels, hardware-based, and injectable technologies constitute second-line options. Tranexamic acid has emerged as an important component of combination treatment protocols for hypermelanosis, enhancing therapeutic efficacy and reducing the risk of relapse. Contemporary fractional radiofrequency devices (so-called ‘microneedle RF') provide controlled thermal effects on the skin, thereby minimizing the risk of post-inflammatory hyperpigmentation, destructing melanosomes and reducing manifestations of pigmentation, while also facilitating restoration of the basement membrane.
Following microneedle RF application, microchannel formation allows for intradermal delivery of agents that regulate melanogenesis, representing a critical element of comprehensive treatment for melanodermia. The combination of microneedle RF lifting and tranexamic acid represents a promising approach for the treatment of hypermelanosis, providing effective correction of hyperpigmented areas, regulation of melanogenesis, and reduction in relapse rates. The effectiveness of this combined modality is illustrated by a clinical case involving a patient with mixed-type melasma of unclear etiology.
Keywords: hypermelanosis, pigmentation, microneedle RF, monopolar RF, tranexamic acid, melasma, retinol, post-inflammatory hyperpigmentation.
For citation: Bychkova N.Yu., Lemytskaya V.E. Fractional RF lifting and tranexamic acid in the treatment of hypermelanosis. Russian Medical Inquiry. 2025;9(6):339–345 (in Russ.). DOI: 10.32364/2587-6821-2025-9-6-7
About the authors:
Natalia Yu. Bychkova — C. Sc. (Med.), dermatologist, cosmetologist, Associate Professor of the Department of Dermatovenerology and Cosmetology with a course in clinical and laboratory diagnostics of the Medical and Biological University of Innovation and Continuous Education, State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; 46, Zhivopisnaya str., Moscow, 123182, Russian Federation; Associate Professor the Department of Dermatovenereology, Allergology and Cosmetology of the Medical Institute, RUDN University; 6, Miklukho-Maklaya str., Moscow, 117198, Russian Federation; ORCID iD 0000-0002-8248-084X
Valentina E. Lemytskaya — dermatovenerologist, cosmetologist, neurologist, Head of the Clinical Department of BTL Russia; 35 build. 2, room. XVIII, Leningradsky Avenue, Moscow, 125284, Russian Federation; ORCID iD 0000-0001-5039-4691
Financial Disclosure: the publication was supported of BTL Russia.
Conflict of interest: V.E. Lemytskaya is an employee of BTL Russia. The second author declares no conflicts of interest.
Received 10.06.2025.
Revised 21.06.2025.
Accepted 28.06.2025.
2. Bala H.R., Lee S., Wong C. et al. Oral Tranexamic Acid for the Treatment of Melasma: A Review. Dermatol Surg. 2018;44(6):814–825. DOI: 10.1097/DSS.0000000000001518
3. Godse K., Sarkar R., Mysore V. et al. Oral Tranexamic Acid for the Treatment of Melasma: Evidence and Experience-Based Consensus Statement from Indian Experts. Indian J Dermatol. 2023;68(2):178–185. DOI: 10.4103/ijd.ijd_266_22
4. Mamdouh Kamal Dawaud S., Hegab D.S., Mohamed El Maghraby G., Ahmad El-Ashmawy A. Efficacy and Safety of Topical Tranexamic Acid Alone or in Combination with Either Fractional Carbon Dioxide Laser or Microneedling for the Treatment of Melasma. Dermatol Pract Concept. 2023;13(3):e2023195. DOI: 10.5826/dpc.1303a195
5. Desai S., Chan L., Handog E. et al. Optimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus. J Drugs Dermatol. 2023;22(4):386–392. DOI: 10.36849/JDD.7104
6. Gaćina K., Krstanović Ćosić A. The use of tranexamic acid in dermatology. Acta Clin Croat. 2023;62(2):368–372. DOI: 10.20471/acc.2023.62.02.16
7. Liu Z. Treatment of Melasma With Q-Switched Laser in Combination With Tranexamic Acid. Dermatol Res Pract. 2025;2025:1883760. DOI: 10.1155/drp/1883760
8. Li Y., Xie H., Deng Z. et al. Tranexamic acid ameliorates rosacea symptoms through regulating immune response and angiogenesis. Int Immunopharmacol. 2019;67:326–334. DOI: 10.1016/j.intimp.2018.12.031
9. Chen T., Xue J., Wang Q. Tranexamic Acid for the Treatment of Hyperpigmentation and Telangiectatic Disorders Other Than Melasma: An Update. Clin Cosmet Investig Dermatol. 2024;17:2151–2163. DOI: 10.2147/CCID.S479411
10. Yuan C., Wang X.M., Yang L.J., Wu P.L. Tranexamic acid accelerates skin barrier recovery and upregulates occludin in damaged skin. Int J Dermatol. 2014;53(8):959–965. DOI: 10.1111/ijd.12099
11. Shin J.U., Park J., Oh S.H., Lee J.H. Oral tranexamic acid enhances the efficacy of low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in Koreans: a randomized, prospective trial. Dermatol Surg. 2013;39(3 Pt 1):435–442. DOI: 10.1111/dsu.12060
12. Wang W.J., Wu T.Y., Tu Y.K. et al. The optimal dose of oral tranexamic acid in melasma: A network meta-analysis. Indian J Dermatol Venereol Leprol. 2023;89(2):189–194. DOI: 10.25259/IJDVL_530_2021
13. Lam T., Medcalf R.L., Cloud G.C. et al. Tranexamic acid for haemostasis and beyond: does dose matter? Thromb J. 2023;21(1):94. DOI: 10.1186/s12959-023-00540-0
14. Mahjoub T.T., Milibary H.H. Oral tranexamic acid in the treatment of hyperpigmentation disorder beyond melasma: A review. J Cosmet Dermatol. 2023;22(4):1157–1162. DOI: 10.1111/jocd.15561
15. Rutnin S., Pruettivorawongse D., Thadanipon K. et al. A Prospective Randomized Controlled Study of Oral Tranexamic Acid for the Prevention of Postinflammatory Hyperpigmentation After Q-Switched 532-nm Nd:YAG Laser for Solar Lentigines. Lasers Surg Med. 2019;51(10):850–858. DOI: 10.1002/lsm.23135
16. Minasyan M., Hogan S., Lal K. Oral Tranexamic Acid for Prevention and Treatment of Postinflammatory Hyperpigmentation. Dermatol Surg. 2024;50(12S):S219–S224. DOI: 10.1097/DSS.0000000000004400
17. Konisky H., Balazic E., Jaller J.A. et al. Tranexamic acid in melasma: A focused review on drug administration routes. J Cosmet Dermatol. 2023;22(4):1197–1206. DOI: 10.1111/jocd.15589
18. Pazyar N., Dezfuly M.B., Hadibarhaghtalab M. et al. Intradermal Injection of 100 mg Tranexamic Acid Versus Topical 4% Hydroquinone for the Treatment of Melasma: A Randomized, Controlled Trial. J Clin Aesthet Dermatol. 2023;16(1):35–40. PMID: 36743976
19. Chandra S., Mysore V., Shah S., Malayanur D.S. R.S. Physics of fractional microneedle radiofrequency — A review. J Cutan Aesthet Surg. 2024;17(3):177–183. DOI: 10.25259/jcas_98_23
20. Manuskiatti W., Pattanaprichakul P., Inthasotti S. et al. Thermal Response of In Vivo Human Skin to Fractional Radiofrequency Microneedle Device. Biomed Res Int. 2016;2016:6939018. DOI: 10.1155/2016/6939018
21. Lee S.J., Goo J.W., Shin J. et al. Use of fractionated microneedle radiofrequency for the treatment of inflammatory acne vulgaris in 18 Korean patients. Dermatol Surg. 2012;38(3):400–405. DOI: 10.1111/j.1524-4725.2011.02267.x
22. Yoon J.E., Kim Y., Kwon S. et al. Senescent fibroblasts drive ageing pigmentation: A potential therapeutic target for senile lentigo. Theranostics. 2018;8(17):4620–4632. DOI: 10.7150/thno.26975
23. Meunier M., Bracq M., Chapuis E. et al. Targeting SDF-1 as an efficient strategy to resolve skin hyperpigmentation issues with Himanthalia elongata extract. J Cosmet Dermatol. 2023;22(2):383–394. DOI: 10.1111/jocd.15357
24. Yamauchi A., Hadjur C., Takahashi T. et al. Human skin melanocyte migration towards stromal cell-derived factor-1α demonstrated by optical real-time cell mobility assay: modulation of their chemotactic ability by α-melanocyte-stimulating hormone. Exp Dermatol. 2013;22(10):664–667. DOI: 10.1111/exd.12232
This work is licensed under a Creative Commons «Attribution» 4.0 License.
